vlp nanoparticles  (InvivoGen)

Journal: Vaccines

Article Title: Current Status of Porcine Reproductive and Respiratory Syndrome Vaccines

doi: 10.3390/vaccines12121387

Figure Lengend Snippet: Key challenges for PRRS vaccines and some possible solutions.

Article Snippet: N, M, GP5 and E proteins , Baculovirus/Sf9 cells , Entrapped in VLP nanoparticles , 3 weeks , 2′,3′-cGAMP VacciGradeTM (Invivogen, USA) , IN , Enhanced viremia associated with IFN-α, IFN-γ, and IL-10. , [ ] .

Techniques: Vaccines, Virus, Modification, Sequencing, Adjuvant, Infection, Selection, Control, Injection, Activity Assay, Multiplex Assay

Journal: Vaccines

Article Title: Current Status of Porcine Reproductive and Respiratory Syndrome Vaccines

doi: 10.3390/vaccines12121387

Figure Lengend Snippet: Some explorations of improving PRRSV inactivated vaccine-induced immune efficacy.

Article Snippet: N, M, GP5 and E proteins , Baculovirus/Sf9 cells , Entrapped in VLP nanoparticles , 3 weeks , 2′,3′-cGAMP VacciGradeTM (Invivogen, USA) , IN , Enhanced viremia associated with IFN-α, IFN-γ, and IL-10. , [ ] .

Techniques: Virus, Emulsion, Infection, Purification, Modification, Expressing, Activation Assay, Immunopeptidomics

Journal: Vaccines

Article Title: Current Status of Porcine Reproductive and Respiratory Syndrome Vaccines

doi: 10.3390/vaccines12121387

Figure Lengend Snippet: The studies of PRRSV subunit vaccines.

Article Snippet: N, M, GP5 and E proteins , Baculovirus/Sf9 cells , Entrapped in VLP nanoparticles , 3 weeks , 2′,3′-cGAMP VacciGradeTM (Invivogen, USA) , IN , Enhanced viremia associated with IFN-α, IFN-γ, and IL-10. , [ ] .

Techniques: Vaccines, Expressing, Enzyme-linked Immunosorbent Assay, Plasmid Preparation, Transformation Assay, Virus, Modification, Adjuvant, Synthesized, Infection

Journal: Vaccine

Article Title: Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact

doi: 10.1016/j.vaccine.2024.126408

Figure Lengend Snippet: The landscape of next-generation influenza vaccines in clinical development, as of April 2024. Each box represents a unique vaccine candidate or group of candidates, associated with their respective developer(s), and includes key characteristics about the candidate, such as indication, route of delivery, high-risk populations tested and antigens included/targeted. Abbreviations: bIRV = bivalent influenza modRNA vaccine; BPL = beta-propriolactone; CIVICs = Collaborative Influenza Vaccine Innovation Centers; HA = haemagglutinin; IIV = inactivated influenza virus vaccine; LAIV = live-attenuated influenza virus vaccine; LNP = lipid nanoparticle; mIRV = monovalent influenza modRNA vaccine; NA = neuraminidase; NIAID = National Institute for Allergy and Infectious Diseases; qIRV = quadrivalent influenza modRNA vaccine; RSV = respiratory syncytial virus; UFV = universal influenza vaccine; VRC = Vaccine Research Center.

Article Snippet: Influenza virus-based vaccines from Icahn School of Medicine at Mount Sinai and GSK, Codagenix, and FluGen target both HA and NA in their candidates, whereas vaccine candidates from NIAID, University of Washington, Emergent BioSolutions using the non-VLP nanoparticles platform and mRNA and recombinant protein candidates from NIAID and Duke CIVICs Vaccine Center and Janssen Vaccines and Prevention and J&J, target HA, including its stem region. ( and Supplemental Table 2).

Techniques: Vaccines, Virus

Journal: Clinical and Experimental Vaccine Research

Article Title: Inside the story about the research and development of COVID-19 vaccines

doi: 10.7774/cevr.2021.10.2.154

Figure Lengend Snippet: Potential protein subunit-based vaccine candidates for COVID-19 in the clinical development pipeline

Article Snippet: The immunogenic composition composed of MERS-CoV nanoparticle VLPs containing at least one trimer of S protein formed by baculovirus overexpression in Sf9 cells was disclosed in patent application WO2015042373 by Novavax in 2015 [ ].

Techniques: Immunopeptidomics, Adjuvant, Recombinant, Vaccines, Bioprocessing, Injection, Plasmid Preparation, Infection

Journal: Environment, Development and Sustainability

Article Title: The COVID-19 puzzle: a global nightmare

doi: 10.1007/s10668-021-01224-3

Figure Lengend Snippet: Latest ongoing clinical trials of different vaccines

Article Snippet: VLP Recombinant Subunit, Full length S trimer/nanoparticle + Matrix M (NVX-CoV2373)/RSV, CCHF, HPV, VZV, EBOV , Novavax|Emergent BioSolutions , Phase I , NCT04368988 , The trials on animal models suggested that this vaccine prevents the attachment of S protein to receptor of host cells as well as destroys the viral wild-type antibodies , WHO ( ); Novavax covid 19 vaccine trial 2020; Anon ( ); Anon ( ) .

Techniques: Clinical Proteomics, Modification, Expressing, Plasmid Preparation, Immunopeptidomics, Virus, Recombinant, Functional Assay